ALMKT:EPA
Mauna Kea Technologies SA
€0.097
arrow_upward
+0.62%(+0.00060) 1D
ኦክቶ 30, 5:35:00 ከሰዓት ጂ ኤም ቲ+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
19.83 ሚ
Avg. vol.
472.04 ሺ
Volume
291.17 ሺ
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26 ሚ
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
19.83 ሚ
Avg. vol.
472.04 ሺ
Volume
291.17 ሺ
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26 ሚ
No. of employees
56
News stories
From web sources and news partners
TradingView
·
ከ1 ሰዓት በፊት
Anthropic files for IPO, aims for $2T valuation on NASDAQ
Crypto News
·
ከ16 ደቂቃዎች በፊት
Bitcoin nears $77,000 as stocks and gold fall in October
Barron's
·
ከ5 ደቂቃዎች በፊት
Subversive S&P 500 Redacted ETF Overview (XXSP)
Bloomberg
·
ከ12 ሰዓቶች በፊት
AI Dip-Buyers Gored as Selling Spasm Caps Third Week of Losses
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA